Staffan Strömberg holds the position of Chief Executive Officer at Infant Bacterial Therapeutics AB.

He is also on the board of Genetic Analysis AS, Cycle Pharmaceuticals AB, Eteboxagu AB and BioGaia Pharma AB and Head- Medical Devices at The Medical Products Agency.

He previously was Vice President for Nicox SA, Head-Medical Devices at Läkemedelsverket, Chief Executive Officer at Tenova Bioplastics AB and Head-Research & Development at Swedish Orphan Biovitrum International AB.

He received a graduate degree and a doctorate from Royal Institute of Technology.